Figure 2.

Cross-sectional estimates and 95% confidence intervals of outcomes, stratified by cystic fibrosis transmembrane conductance regulator modulator use at baseline (iva = ivacaftor monotherapy). Times shown are baseline and the 6-month post-elaxaftor/tezacaftor/ivacaftor visit. Participants who were pregnant at a visit (n = 2 at baseline; n = 7 at 6 mo) were excluded from analyses of body mass index (BMI). Dotted lines show limits of the instrument (sweat chloride [SwCl] and Cystic Fibrosis Questionnaire–Revised, Respiratory Domain [CFQ-R RD]) or thresholds (BMI 25 for overweight, BMI 18 for underweight, and BMI z-score 0 for median). Lum = lumacaftor; ppFEV₁ = percent predicted FEV₁; Tez = tezacaftor.